What’s Vulnerable › Vulnerabilities

CVE-2026-50034: Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Cleartext Transmission of Sensitive Information

• Severity: medium (CVSS 6.5 v3.1)
• Exploited in the wild: not listed in CISA KEV
• EPSS: 0.2% probability of exploitation in the next 30 days
• Public exploit or detection template: none known
• Published: 2026-06-19 · updated 2026-10-25
• Weakness: CWE-319

Description

An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.

Affected products

• Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT): 0x0110_v1.1.0

References

• https://github.com/cisagov/CSAF/blob/develop/csaf_files/OT/white/2026/icsma-26-169-01.json
• https://www.apollopharmacy.in/contact-us
• https://www.cisa.gov/news-events/ics-medical-advisories/icsma-26-169-01
• https://www.cisa.gov/news-events/news/understanding-bluetooth-technology

Get alerted when CVE-2026-50034 or the next vulnerability affects your stack